UroGen Pharma (LTS:0XOD) Purchase Of Business : $0.00 Mil (TTM As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is UroGen Pharma Purchase Of Business?

UroGen Pharma's purchase of business for the three months ended in Mar. 2025 was $0.00 Mil. It means UroGen Pharma spent $0.00 Mil on purchasing business. UroGen Pharma's purchase of business for the trailing twelve months (TTM) ended in Mar. 2025 was $0.00 Mil.

Compared with last quarter ($0.00 Mil in Dec. 2024 ), UroGen Pharma spent the same money on purchasing business in Mar. 2025 ($0.00 Mil).

UroGen Pharma Purchase Of Business Historical Data

The historical data trend for UroGen Pharma's Purchase Of Business can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UroGen Pharma Purchase Of Business Chart

UroGen Pharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Purchase Of Business

Get a 7-Day Free Trial

UroGen Pharma Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Purchase Of Business	Get a 7-Day Free Trial															-	-	-	-	-

UroGen Pharma Purchase Of Business Calculation

The amount used to purchase business.

Purchase Of Business for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

UroGen Pharma Purchase Of Business Related Terms

Thank you for viewing the detailed overview of UroGen Pharma's Purchase Of Business provided by GuruFocus.com. Please click on the following links to see related term pages.

UroGen Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UroGen Pharma Ltd (LTS:0XOD) » Definitions » Purchase Of Business

Comparable Companies

Traded in Other Exchanges

URGN:USA UR8:Germany

Address

400 Alexander Park Drive, 4th Floor, Princeton, NJ, USA, 08540

Website

https://www.urogen.com

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

UroGen Pharma Headlines

No Headlines